Boxiong Xie

机构：Beijing Jiaotong University

发表论文 32 篇 · 总被引 416 次 · h-index 9

代表论文

• Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial (2022 · BMC Medicine · 被引 68)
• Single-port video-assisted thoracic surgery in 1063 cases: a single-institution experience (2016 · European Journal of Cardio-Thoracic Surgery · 被引 64)
• Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis (2022 · Cancer Cell International · 被引 55)
• [Shanghai Pulmonary Hospital Experts Consensus on the Management of Ground-Glass Nodules Suspected as Lung Adenocarcinoma (Version 1)]. (2018 · PubMed · 被引 46)
• Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients (2018 · Heliyon · 被引 41)
• Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer (2020 · Aging · 被引 39)